K Markey, A Douglas-Bardsley, J Hockley, D Le Tallec, A Costanzo
{"title":"标准化CHO细胞聚类试验中百日咳毒素BRP第1批的校准。","authors":"K Markey, A Douglas-Bardsley, J Hockley, D Le Tallec, A Costanzo","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The European Pharmacopoeia (Ph. Eur.) pertussis toxin (PT) Biological Reference Preparation (BRP) is used as a working standard for safety testing of acellular pertussis vaccines as prescribed in the Ph. Eur. monographs 1356 \"Pertussis vaccine (acellular, component, adsorbed)\" and 1595 \"Pertussis vaccine (acellular, co-purified, adsorbed)\". The BRP was calibrated in 2006 in the murine histamine sensitisation test (HIST) against the World Health Organization (WHO) 1<sup>st</sup> International Standard (IS) for PT. In recent years, there have been increasing efforts to replace the <i>in vivo</i> test with <i>in vitro</i> methods. The Chinese hamster ovary (CHO) cell clustering assay has been used for many years by manufacturers to monitor residual PT activity in detoxified non-adjuvanted bulks. More recently a standardised protocol has been developed for this assay and a PT reference preparation was needed. Due to low stocks, the WHO 1<sup>st</sup> International Standard for Pertussis Toxin (JNIH-5) needed to be replaced and therefore a joint study between the European Directorate for the Quality of Medicines & HealthCare (EDQM) and WHO was initiated to calibrate the PT BRP for the CHO clustering assay and to replace the IS. The collaborative study involved 14 laboratories from Europe, North America and Asia. The outcome of the study confirmed that the BRP is suitable for use as a reference preparation in the CHO clustering assay. The material was assigned a potency of 1360 IU per vial for the CHO clustering assay.</p>","PeriodicalId":39192,"journal":{"name":"Pharmeuropa bio & scientific notes","volume":"2018 ","pages":"112-123"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay.\",\"authors\":\"K Markey, A Douglas-Bardsley, J Hockley, D Le Tallec, A Costanzo\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The European Pharmacopoeia (Ph. Eur.) pertussis toxin (PT) Biological Reference Preparation (BRP) is used as a working standard for safety testing of acellular pertussis vaccines as prescribed in the Ph. Eur. monographs 1356 \\\"Pertussis vaccine (acellular, component, adsorbed)\\\" and 1595 \\\"Pertussis vaccine (acellular, co-purified, adsorbed)\\\". The BRP was calibrated in 2006 in the murine histamine sensitisation test (HIST) against the World Health Organization (WHO) 1<sup>st</sup> International Standard (IS) for PT. In recent years, there have been increasing efforts to replace the <i>in vivo</i> test with <i>in vitro</i> methods. The Chinese hamster ovary (CHO) cell clustering assay has been used for many years by manufacturers to monitor residual PT activity in detoxified non-adjuvanted bulks. More recently a standardised protocol has been developed for this assay and a PT reference preparation was needed. Due to low stocks, the WHO 1<sup>st</sup> International Standard for Pertussis Toxin (JNIH-5) needed to be replaced and therefore a joint study between the European Directorate for the Quality of Medicines & HealthCare (EDQM) and WHO was initiated to calibrate the PT BRP for the CHO clustering assay and to replace the IS. The collaborative study involved 14 laboratories from Europe, North America and Asia. The outcome of the study confirmed that the BRP is suitable for use as a reference preparation in the CHO clustering assay. The material was assigned a potency of 1360 IU per vial for the CHO clustering assay.</p>\",\"PeriodicalId\":39192,\"journal\":{\"name\":\"Pharmeuropa bio & scientific notes\",\"volume\":\"2018 \",\"pages\":\"112-123\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmeuropa bio & scientific notes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmeuropa bio & scientific notes","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
欧洲药典(Ph. Eur.)百日咳毒素(PT)生物参比制剂(BRP)被用作欧洲药典(Ph. Eur.)规定的无细胞百日咳疫苗安全测试的工作标准。专著1356“百日咳疫苗(无细胞,组分,吸附)”和1595“百日咳疫苗(无细胞,共纯化,吸附)”。BRP于2006年在小鼠组胺致敏试验(HIST)中根据世界卫生组织(WHO) PT第一国际标准(IS)进行校准。近年来,越来越多的人努力用体外方法取代体内试验。中国仓鼠卵巢(CHO)细胞聚类试验已被制造商用于监测脱毒无佐剂散装中残留的PT活性多年。最近,已经制定了该测定的标准化方案,并且需要PT参比制剂。由于库存不足,需要更换世卫组织第1版百日咳毒素国际标准(JNIH-5),因此启动了欧洲药品和卫生保健质量理事会(EDQM)和世卫组织之间的联合研究,以校准用于CHO聚类分析的PT BRP并取代IS。这项合作研究涉及来自欧洲、北美和亚洲的14个实验室。研究结果证实,BRP适合作为CHO聚类分析的参考制剂。该材料的效价为1360 IU /瓶,用于CHO聚类分析。
Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay.
The European Pharmacopoeia (Ph. Eur.) pertussis toxin (PT) Biological Reference Preparation (BRP) is used as a working standard for safety testing of acellular pertussis vaccines as prescribed in the Ph. Eur. monographs 1356 "Pertussis vaccine (acellular, component, adsorbed)" and 1595 "Pertussis vaccine (acellular, co-purified, adsorbed)". The BRP was calibrated in 2006 in the murine histamine sensitisation test (HIST) against the World Health Organization (WHO) 1st International Standard (IS) for PT. In recent years, there have been increasing efforts to replace the in vivo test with in vitro methods. The Chinese hamster ovary (CHO) cell clustering assay has been used for many years by manufacturers to monitor residual PT activity in detoxified non-adjuvanted bulks. More recently a standardised protocol has been developed for this assay and a PT reference preparation was needed. Due to low stocks, the WHO 1st International Standard for Pertussis Toxin (JNIH-5) needed to be replaced and therefore a joint study between the European Directorate for the Quality of Medicines & HealthCare (EDQM) and WHO was initiated to calibrate the PT BRP for the CHO clustering assay and to replace the IS. The collaborative study involved 14 laboratories from Europe, North America and Asia. The outcome of the study confirmed that the BRP is suitable for use as a reference preparation in the CHO clustering assay. The material was assigned a potency of 1360 IU per vial for the CHO clustering assay.